{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'listings and figures will be described in the statistical analysis plan (SAP). The SAP will be', 'developed and finalized before database lock and will describe the subject analysis sets to be', 'included in the analyses, and procedures for accounting for missing, unused, and spurious data.', 'This section is a summary of the planned statistical analyses of the primary and secondary', 'endpoints.', 'The default summary statistics for continuous variables includes number of contributing', 'observations (n), mean, standard deviation (SD), median, minimum, and maximum. (See', 'Section 9.4.7 for PK).', 'For categorical variables, the number and percentage (the percentage of subjects in each category', 'relative to the total number of subjects in the relevant analysis set or relative to the total number', 'of subjects in the relevant analysis set, with assessments available [where appropriate]) in each', 'category will be the default summary presentation.', 'Unless otherwise specified, \"baseline\" is defined as the last observed value of the parameter of', 'interest prior to the first intake of study drug (this includes unscheduled visits). For numerical', 'variables, change from Baseline will be calculated as the difference between the value of interest', 'and the corresponding baseline value.', 'Point estimates will be accompanied with 2-sided 95% confidence interval (CIs), where', 'applicable.', 'In the case of normality assumption violations, appropriate non-parametric methods will be used', 'for analysis.', 'All data will be presented in by subject listings.', '9.4.1', 'Subject Disposition', 'A tabular presentation of the subject disposition will be provided. It will include the number of', 'subjects screened, enrolled, treated, completed as well as the number of dropouts, with reasons', 'for discontinuation, and major protocol deviations or violations.', 'A listing will be presented to describe dates of screening, assigned treatment, screen failed with', 'reason, completion or early withdrawal, and the reason for early discontinuation, if applicable,', 'for each subject. A list of protocol deviations/violations will be identified and discussed with the', 'Investigator/AnaptysBio Inc. in dry-run to categorize as major or minor and the same will be', 'reported.', '9.4.2', 'Subject Characteristics and Medical History', 'Subject characteristics obtained at Screening will be summarized for all subjects taking', 'ANB019. Subject characteristics may include, but are not limited to age, gender, height, weight,', 'and BMI.', '29 October 2019', '49']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Summaries will include descriptive statistics for continuous variables (sample size [n], mean,', 'SD, median, minimum, and maximum) and for categorical variables (sample size, frequency, and', 'percent).', 'Medical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA)', 'dictionary latest version and listed for all subjects.', '9.4.3', 'Concomitant Medication', 'All medications will be coded using the World Health Organization Drug Dictionary and', 'Anatomical Therapeutic Chemical (ATC) system. Each medication will be classified as prior', 'medication if it is stopped prior to the first dose of study drug, or as concomitant medication if it', 'is ongoing at the time of the first dose or is started after the first dose of study drug. Prior,', 'concomitant and rescue medications will be summarized by ATC level 2 categories and', 'preferred name.', 'A listing of prior, concomitant, and rescue medications will be presented.', '9.4.4', 'Efficacy Analyses', '9.4.4.1', 'Analysis of Primary Efficacy Enpoints', 'The primary efficacy endpoint is the proportion of subjects achieving clinical response at', 'Weeks 4 and 16. Clinical response is defined as \"Very much improved\", \"Much improved\", and', '\"Minimally improved\" on CGI scale according to modified JDA severity index total score. The', 'number and percentage of subjects achieving clinical response will be summarized in tabular', 'form at Weeks 4 and 16. Each subjects CGI score will be plotted at all study visits.', '9.4.4.2', 'Analysis of Secondary Efficacy Enpoints', 'Following are the secondary efficacy endpoints:', 'Change in modified JDA severity index total skin lesions score (sum of erythema, erythema', 'with pustules, edema) at all study visits.', \"Descriptive statistics will be presented at all study visits. Each subject's modified JDA severity\", 'index total skin lesion score will be plotted at all study visits.', 'Change in affected BSA of erythema with pustules, erythema, and edema as measured by', 'modified JDA severity index score at all study visits:', \"Descriptive statistics will be generated at all study visits. An overlay plot of each subject's value\", 'over all study visits will be generated for each component score.', 'Change in total and individual scores in systemic manifestations and laboratory findings as', 'measured by modified JDA severity index at all study visits.', '29 October 2019', '50']\n\n###\n\n", "completion": "END"}